Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422669 · ClinicalTrials.gov registry record · NA
Optimize RV Selective Site Pacing Clinical Trial
A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Terminated
- Registry status
- NA
- Development phase
- 205
- Enrollment target
NCT00422669 is a NA study that was terminated before completion, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 205 participants.
The verdict
NCT00422669, a NA study, was terminated before completion, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- TERMINATED
- Registry status
- NA
- Development phase
- 205 participants
- Enrollment target
Study Summary
The purpose of the Optimize RV study is to determine the long-term effect of selective site pacing. Selective site pacing refers to which area of the right ventricle the lead is placed. The goal of select site pacing is to improve how the heart contracts when paced in the ventricle. By pacing in select sites, it is possible to better copy the natural pattern of contraction of the heart.
Interventions
- DEVICE Medtronic SelectSecure 3830 Lead
- DEVICE Medtronic Dual-Chamber Pacemaker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422669
The ClinicalTrials.gov registry entry for NCT00422669 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Medtronic SelectSecure 3830 Lead is the first listed.
NCT00422669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422669 about?
NCT00422669 is a clinical study titled "Optimize RV Selective Site Pacing Clinical Trial". The purpose of the Optimize RV study is to determine the long-term effect of selective site pacing. Selective site pacing refers to which area of the right ventricle the lead is placed. The goal of select site pacing is to improve how the heart contracts when paced in the ventricle. By pacing in sel...
What is the current status of trial NCT00422669?
This trial is currently terminated. It is a NA study. The enrollment target is 205 participants. The study started on 2007-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00422669?
The interventions under investigation include: Medtronic SelectSecure 3830 Lead (DEVICE), Medtronic Dual-Chamber Pacemaker (DEVICE).
Who is sponsoring clinical trial NCT00422669?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.